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Arsenitep27 is a cyclin-dependent kinase (CDK) inhibitor that suppresses a cell's transition from G0 to S phase, therefore
acting as a tumor suppressor. Our most recent studies demonstrate that upon arsenite exposure, p27 suppresses
Hsp27 and Hsp70 expressions through the JNK2/c-Jun- and HSF-1-dependent pathways, suggesting a novel
molecular mechanism underlying the tumor suppressive function of p27 in a CDK-independent manner. We
found that p27-deﬁciency (p27−/−) resulted in the elevation of cyclooxygenase-2 (COX-2) expression at
transcriptional level, whereas the introduction of p27 brought back COX-2 expression to a level similar to that
of p27+/+cells, suggesting that p27 exhibits an inhibitory effect onCOX-2 expression. Further studies identiﬁed
that p27 inhibition of COX-2 expression was speciﬁcally due to phosphorylation of transcription factor cAMP
response element binding (CREB) phosphorylation mediated by p38β and p38δ. These results demonstrate a
novel mechanism underlying tumor suppression effect of p27 and will contribute to the understanding of the
overall mechanism of p27 tumor suppression in a CDK-independent manner.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
Arsenic is a metalloid chemical element that widely occurs in
water, soil, minerals, and industrial products [1]. It mostly remains
as sulﬁde or oxide in the environment. Some of the most common
arsenic compounds are referred to as arsenite, which denotes any salt
of arsenious acid composed of trivalent arsenic [2]. Though arsenite in
subtoxic doses has been developed for medical use, its toxicity [3]
and environmental carcinogenic effect [4] still have to be considered.
Occupational exposure occurs in industries involving nonferrous metal
alloys, electronic semiconductor manufacture, and wood preservation;
and is a known cause of skin and epithelial cancers [5]. Generation of
reactive oxygen species, genetic toxicity, and alteration of signaling
pathways caused by arsenite are potentially responsible for arsenite-
induced carcinogenic effects [6]. Our previous studies have shown that
arsenite exposure initiates activation of several signal pathways and
further alters downstream gene expression and cell transformation
[7–9]. Cyclooxygenase-2 (COX-2) is known as a prostaglandin endoper-
oxide synthase-2 (PTGS-2). COX-2 is upregulated during inﬂammatory
responses, but is undetectable under normal conditions [10]. COX-2 isntacted at Tel.: +1 845 731
mingao@yahoo.com (J. Gao),
rights reserved.found to be highly overexpressed in various cancer tissues and cells.
Further studies from both in vitro and in vivo show that COX-2 and its
products, such as prostaglandin E2 (PGE2) and H2 (PGH2), are involved
in carcinogenesis at both the tumor promotion and progression stages,
through multiple mechanisms that include anti-apoptosis and media-
tion of cancer cell proliferation [11,12]. As an inducible enzyme, COX-2
expression is precisely regulated by its upstream pathways leading to
alteration of transcription factors. Our previous studies have demon-
strated that arsenite exposure induces COX-2 expression via the NFAT-
dependent pathway in human bronchial epithelial Beas-2B cells, while
COX-2 induction by arsenite in mouse epidermal Cl41 cell relies on
NFκB activation [13]. Together with other ﬁndings indicating that
COX-2 protein levels are also regulated at its mRNA stability, protein
translation, and protein degradation, COX-2 expression is controlled
by multiple pathways at various levels, which depend on cell types
and stimuli.
p27, a member of the Cip/Kip family of CDK inhibitor proteins, acts
as a CDK inhibitor, which affects the function of cyclin protein, leading
to cell cycle arrest in G1 phase [14,15]; thus, p27 is considered as a
tumor suppressor [16,17]. However, recent studies also reveal that
p27 functions in a CDK-independent manner [18,19]. Our most recent
studies demonstrate that p27 suppressedHsp27 andHsp70 expressions
at the transcriptional level speciﬁcally through JNK2/c-Jun- and
HSF-1-dependent pathways upon arsenite exposure, which provides
an additional important molecular mechanism for the tumor suppres-
sive function of p27 [7]. In this study, we investigated the potential
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involved in inﬂammation and carcinogenesis.2. Materials and methods
2.1. Cell culture and reagents
Mouse epidermal JB6 Cl41 cells were cultured in Minimal Essential
Medium (MEM)with 5% FBS.Wild type ofMEFs and various lines of the
corresponding knockout cells p27Δ51/Δ51 (p27−/−) were described
in our previous studies [7]; p38α−/−, p38β−/− and p38δ−/−
were provided by Dr. Jiahuai Han from School of Life Sciences, Xiamen
University [20]. All MEFs and their stable transfectantsweremaintained
in Dulbecco'sModiﬁed EagleMedium (DMEM) supplementedwith 10%
Fetal Bovine Serum (FBS), 2 mM L-glutamine, and 25 μg/ml of gentami-
cin at 37 °C in a 5% CO2 incubator. The cultures were dissociated with
trypsin and transferred to new75-cm2 cultureﬂasks (Fisher, Pittsburgh,
PA) twice a week. FBS was purchased from Nova-Tech (Grand Island,
NE). Sodium arsenite was purchased from Aldrich (Milwaukee, WI).
The inhibitor of JNK, SP600125, inhibitor of p38 kinase, SB202190, and
actinomycin D were from Calbiochem (La Jolla, CA). The inhibitor for
MEK1/2, PD98059, was from Cell Signaling Technology (Beverly, MA).
Antibodies against non-phosphorylated c-Jun, CREB, JNK1/2, p38,
MKK3 phosphor-c-Jun at Ser63/Ser73, phosphorylated CREB at Ser133,
phosphor-JNK at Thr183/Tyr185, phosphor-ERK at Thr202/Tyr204
phosphor-p38 kinase at Thr180/Tyr182, and phosphor-MKK3 at Ser
189/MKK6 at Ser 207 were purchased from Cell Signaling Technology
(Beverly, MA); antibodies speciﬁcally against Jun B, Fra-1, and p27
were purchased from Santa Cruz Biotechnology Inc. (Santa Cruz, CA).
Antibody against β-actin was from Sigma; antiserum against COX-2
was from Cayman Chemical Co (Ann Arbor, MI).2.2. Construct and transfection
Dominant negativemutant p38 (DN-p38) plasmid, were generously
provided by Dr. Roger J. Davis (University of Massachusetts Medical
School) [21]. The above plasmid, aswell as the empty vector, was stably
transfected into p27−/− cells together with puromycin-resistant plas-
mid. The stable transfectants of DN-p38were established by puromycin
selection (4 μg/ml) and named as p27−/− (DN-p38). The CREB shRNA
and its nonsense plasmid control were purchased from Open
Biosystems (Thermo Fisher Scientiﬁc, Huntsville, AL). p27−/− MEFs
were transfectedwith these plasmids to establish the CREB knockdown
cell line which was named as p27−/− (shCREB), as well as its control
cell line, after selection by puromycin (2 μg/ml). The shRNA-p27
(targeting mouse CGC AAG TGG AAT TTC GAC TT) was from Open
Biosystems (Thermo Fisher Scientiﬁc, Huntsville, AL), and was
transfected stably into Cl41 cells. The stable transfectantswere obtained
by puromycin selection (8 μg/ml). COX-2 luciferase reporter containing
human COX-2 promoter sequences from −327 to +59 relating to
the transcription initiation was kindly provided by Prof. Kotha
Subbaramaiah (Weill Medical College of Cornell University) [22].2.3. Recombinant adenovirus construct and infection
The AdEasy vector system (Quantum Biotechnologies, Montreal,
Canada) and p27 cDNA were used to construct the recombinant
adenoviral (Ad) vector. Shuttle plasmids were ﬁrstly electroporated
into the recombinogenic Escherichia coli BJ5183 strain and selected.
The virus was then transfected into HEK293 cells. Supernatant of
lysed HEK293 cells were saved at −80 °C until they were used for
infection. Detailed information regarding the plasmid, as well as the
processes used for virus ampliﬁcation, screening, and infection were
described in our previous study [7].2.4. Cell proliferation assay
p27+/+ and p27−/− (Δ51) cells were suspended in DMEM
supplemented with 10% FBS in a concentration of 5 × 104/ml. Cells
in 100 μl DMEM suspension was cultured to each well of 96 well
plates. After 12 h of incubation at 37 °C in a humidiﬁed atmosphere of
5% CO2, cells were exposed to arsenite in a concentration of 20 μM for
6 to 12 h. The exposed cells were lysed with 50 μl lysis buffer, and the
proliferation of the cells was measured using CellTiter-Glo Luminescent
Cell Viability Assay kit (Promega,Madison,WI, USA)with a luminometer
(Wallac 1420 Victor2 multipliable counter system; PerkinElmer Life
and Analytical Sciences, Inc., Waltham, MA, USA). The results are
expressed as proliferation relative to control medium (proliferation
index).
2.5. Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted from the cells using Trizol reagent
(Invitrogen, Carlsbad, California). Total cDNAs were synthesized by
ThermoScript™ RT-PCR system (Invitrogen, Carlsbad, California).
The mRNA amount present in the cells was measured by semi-
quantitative RT-PCR. The primers for mouse cox-2 were 5′-TCC TCC
TGG AAC ATG GAC TC-3′ and 5′-GCT CGG CTT CCA GTA TTG AG-3′.
The control mouse β-actin mRNA was also detected by RT-PCR using
the primers (5′-GAC GAT GAT ATT GCC GCA CT-3′ and 5′-GAT
ACC ACG CT T GCT CTG AG-3′). The PCR products were separated on
2% agarose gels, stained with EB. The results were displayed with
the Alpha Innotech SP image system (Alpha Innotech Corporation.,
San Leandro, CA) and the densitometric analyses of the product
bands were conducted using the software of ImageQuant 5.2 (GE
Healthcare).
2.6. Luciferase reporter assay
Wild type MEF cells, p27−/− MEFs, p27−/− (DN-p38) cells,
p27−/− (shCREB) cells and their corresponding p27−/− MEFs
transfected with control vector were transfected or co-transfected
with COX-2 promoter luciferase reporter. Puromycin selection for
establishment of stable transfectants for p27−/− (DN-p38) cells,
p27−/− (shCREB) cells and their corresponding p27−/− control
MEFs is described in the “Construct and transfection” section. Cellular
lysates were prepared after arsenite treatment and luciferase activities
were determined using a luminometer (Wallac 1420Victor 2multilabel
counter system). For wild type MEFs and p27−/− MEFs, the arsenite
treatment was performed 24 h after the transient transfection.
2.7. Nuclear/cytosol fractionation
For preparation of cell nuclear/cytosol protein fractionations,
p27+/+ and p27−/− MEFs were cultured in 10 mm dishes till 80%
conﬂuent. Cells were then exposed to arsenite (20 μM) for 9 h, and
were harvested and processed with a Nuclear/Cytosol kit (BioVision,
Mountain, CA) to extract the nuclear and cytosol protein as described
in our previous studies [23].
2.8. Western blotting
MEFs and their transfectants were plated in 6-well plates and cul-
tured in normal 10% FBS DMEM to70–80% conﬂuence. After treatments
indicated, cells were extracted and total protein was quantiﬁed with a
DC protein assay kit (Bio-Rad, Hercules, CA). Western blotting was
carried out as previously described [24]. Primary antibody-bound pro-
teins were detected using an alkaline phosphatase-linked secondary
antibody and an ECFWestern blotting system (Amersham, Piscataway,
NJ). The results shown were representative of three independent
experiments.
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3.1. p27 suppressed COX-2 induction by arsenite
Since skin is a well-known major target of arsenite, we determined
COX-2 induction in mouse epidermal Cl41 cells by arsenite at either
low dose (0.5–2 μM) chronic exposures or relative high dose (20 μM)
acute exposure. The results showed that an acute exposure to 20 μM
arsenite or repeated chronic exposure to 1 μM of arsenite for two
months induced a similar level of COX-2 protein expression in Cl41
cells (Fig. 1A and B). Thus, we used 10–20 μM arsenite in current
study. Genetic knockout of a speciﬁc gene is a very unique molecular
approach to address the function of such gene in a biological function.
Spontaneous immortalization of cell line from a speciﬁc gene knockout
mouse has long been considered as one of the most efﬁcient and avail-
able approach for establishing gene knockout MEFs. To determine the
potential role of p27 in the regulation of COX-2 induction by arsenite,
we employed p27−/−MEFs and its accordingly wild type (p27+/+)
MEFs that has been used in our previous studies [7] and was also indi-
cated in the results in Western blot and RT-PCR assays (Fig. 1C and D).
Cell treatment with 20 μM arsenite for 9 h resulted in COX-2 induction
in p27+/+ cells. And this induction was markedly increased in
p27−/− cells (Fig. 1E), suggesting that p27 expression provided a
strong inhibitory effect on COX-2 induction by arsenite. To conﬁrm
that increased COX-2 expression in p27−/− MEFs is speciﬁcally due
to p27 deﬁciency, adeno-p27 virus was applied to p27−/− MEFs to
recover p27 expression. As shown in Fig. 1F, wild type p27 protein
was detected in p27−/− cells infected with the adeno-p27 virus.
Restoration of p27 expression in p27−/−MEFs dramatically inhibited
COX-2 protein expression upon arsenite exposure compared to that in
its parental p27−/−MEFs (Fig. 1F). The results obtained from ATPase
assay showed that treatment of cells with 20 μM for 12 h did not lead
to signiﬁcant cell death in both p27+/+ and p27−/− (Δ51) cells
(Fig. 1G). To conﬁrm this result in Cl41 cell, we used speciﬁc mouse
p27 shRNA to knockdown p27 expression in Cl41 cells to determinep27+/+  p27-/-(Δ51)
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Fig. 1. p27 inhibited arsenite-induced COX-2 expression. (A and B), Cl 41 cells were repeat
arsenite for 24 h (A) or with 10–20 μM arsenite for 12 h. The cells were extracted and
RT-PCR (C) andWestern blotting (D). β-Actin was used as a loading control. (E), p27+/+ an
expression was determined by Western blotting. (F), Twenty-four hours after p27−/−ME
vector control, the cells were treated with arsenite for 12 h. COX-2 and p27 protein expr
exposed to 20 μM arsenite for indicated times. The exposed cells were lysed with 50 μl lysis
Cell Viability Assay kit with a luminometer as described in Materials and methods section.
expression in Cl41 cells stably transfected with p27 shRNA was identiﬁed by Western blot (
The COX-2 protein induction was determined by Western blotting. The experiments werewhether the inhibitory effect of p27 on COX-2 induction by arsenite
could be veriﬁed in Cl41 cells. As expected, introduction of p27 shRNA
into Cl41 cells led to over 80% reduction of p27 protein expression in
comparison with that in nonsense shRNA transfectant Cl41 sh-p27
(Fig. 1H). Consistently, knockdown of p27 expression in Cl41 (Cl41
sh-p27) cells also increased COX-2 protein induction upon arsenite treat-
ment compared to Cl41-nonsense transfectant (Fig. 1I). These results
demonstrate that p27 expression inhibits COX-2 induction via arsenite
exposure.
3.2. p27 suppressed COX-2 expression at transcription level
To elucidate the molecular mechanisms underlying p27 inhibition
of COX-2 induction by arsenite, we ﬁrst determined the COX-2 mRNA
levels in both p27+/+ and p27−/− MEFs upon arsenite treatment.
Though basal level of COX-2mRNA is higher in p27+/+MEFs, arsenite
exposure only slightly upregulated its expression 9 h after exposure.
However in p27−/− MEFs arsenite treatment signiﬁcantly increased
COX-2 mRNA expression by folds at both 6 h and 9 h of exposure in
p27−/− MEFs under the same experimental conditions, which is
consistent with the COX-2 protein expression (Fig. 2A and B). Since
the above results showed that p27 inhibits cox-2 mRNA levels upon
arsenite exposure, we evaluated the cox-2 mRNA stabilities in both
p27+/+ and p27−/− cells. As shown in Fig. 2C, treatment of cells
with actinomycin D (20 μg/ml) resulted in a cox-2 mRNA degradation
in p27+/+ cells, and this degradation was markedly increased in
p27−/− cells (Fig. 2C). The half life of cox-2 mRNA (T1/2) in p27+/+
cells was 2.61 h, whereas it was reduced to 1.44 h in p27−/− cells
(Fig. 2D). Those results suggest that RNA stability does not contribute
to p27 inhibition of cox-2 mRNA induction upon arsenite exposure.
We then tested cox-2 promoter activity in both p27+/+ and
p27−/−MEFs through a luciferase reporter assay. The results showed
that in p27−/− MEFs, COX-2 is induced more than 5 folds while in
p27+/+ cells there was no induction observed, indicating that the
reason for the difference in COX-2 levels in these cells is discriminationp27
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Fig. 2. p27 inhibited COX-2 transcription in response to arsenite. (A), p27+/+ and p27−/− MEFs were treated with 20 μM of arsenite for 3, 6, and 12 h. RT-PCR was carried out
to determine the mRNA levels of cox-2 expression. The PCR products were separated over 2% agarose gels, stained with ethidium bromide. (B), The densitometric analyses of the
product bands were conducted using the software of ImageQuant 5.2 (GE Healthcare). (C), After pretreatment with 10% FBS for 9 h, p27+/+ and p27−/− cells were treated with
actinomycin D of 20 μg/ml for time periods indicated. RT-PCR was carried out to determine the mRNA levels of cox-2 expression. The PCR products were separated over 2% agarose
gels, stained with ethidium bromide. (D), The relative RNA level of cox-2 was determined by ImageQuant 5.2 (GE Healthcare). Natural logarithm of ratio [cox-2]t/[cox-2]0 was
plotted against the time and the half life of cox-2 mRNA was calculated via linear regression. (E), p27+/+ and p27−/− cells stably transfected with COX-2 luciferase reporter were
treated with arsenite for 6 h. The luciferase activities were then evaluated, and the results are presented as luciferase activity relative to the medium control. Each bar indicated the
mean ± S.D. of triplicate assay wells. “*” indicated signiﬁcant difference (P b 0.05). The experiments were performed at least three times.
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the DNA sequence of NFκB, NF-IL6, and CRE binding site. This is consis-
tent with the fact that NFκB, CREB, and AP-1 are major transcription
factors involved in regulation of COX-2 transcription [25–28]. This is
indicative of the potential involvement of such transcription factors in
COX-2 induction via this process.
3.3. p27 suppressed p38 phosphorylation by arsenite
Todetermine signaling involved in the upregulation of COX-2 induc-
tion in p27−/− MEF due to arsenite exposure, we ﬁrst examined the
potential effects of the constitutive expression of p27 on MAPK phos-
phorylation by infection of p27−/− cells with either GFP adenovirus
or GFP-p27 adenovirus. As shown in Fig. 3A and B, arsenite treatment
resulted in activation of p38, JNK and ERK to certain extents in
p27−/− cells infected with control adenoviral vectors in various time
points, whereas the activation was dramatically impaired in p27−/−
cells infected with adeno-p27 virus. Consistently, increased COX-2
induction in p27−/− (vector) cells was also dramatically reduced in
p27−/− cells infectedwith adeno-p27 virus (Fig. 3A and B). As p38 up-
stream kinases, MKK3/6 phosphorylation was also upregulated upon
arsenite exposure in p27−/− (vector) cells, whereas this upregulation
was impaired in the p27−/− cells infected with adeno-p27 virus
(Fig. 3A and B), suggesting that p27might downregulate p38 activation
by targeting MKK3/6 or their upstream kinases. Further elucidation of
p27 target for mediating MKK3/6-p38 activation is currently undergo-
ing in our laboratory. To determine whether inhibition of any of these
MAPKs is associated with p27-regulated COX-2 expression, we ﬁrst
employed MAPK chemical inhibitors. The results suggested that inhibi-
tion of p38 phosphorylation by its inhibitor SB202190 is positively asso-
ciated with downregulation of arsenite-induced COX-2 expression in
p27−/− cells, whereas either inhibition of JNKs by its inhibitor
SP600125 or inhibition of ERK phosphorylation by its inhibitor
PD98059 did not show any observable correlation with COX-2 expres-
sion (Fig. 3C). These results suggested that p27 might suppress p38 in
cells. This notionwas further supported by data showing that p38 phos-
phorylation by arsenite was remarkably increased in p27−/− cells and
Cl41 p27 knockdown cells compared to their corresponding parentalcells (Fig. 3D and E). Collectively, our results indicated that p27 expres-
sion suppressed p38 phosphorylation upon arsenite exposure in cells.
However, chemical inhibitormerely provided a clue showingpotentially
responsibility of kinases. Also, p38 has different isoforms, some of which
are not signiﬁcantly suppressed by inhibitor we applied above. There-
fore, to further prove that p38 is actually involved in COX-2 activation,
we used the dominant negative p38 to interfere with the endogenous
p38 function, which would be discussed in the next part of the results.
3.4. p38β and p38δ, but not p38α, was crucial for arsenite-induced CREB
phosphorylation and COX-2 expression
Since the above results suggested that p27 inhibited arsenite-
induced COX-2 expression at the transcriptional level, we determined
which transcription factor is involved in p27 downregulation of COX-2
expression. Consistent with the p38 inhibitor on COX-2 expression,
SB202190 treatment of p27−/− cells showed a speciﬁc inhibition of
arsenite-induced CREB phosphorylationwithout affecting CREB protein
expression, however it did not show anobservable effect on c-Jun phos-
phorylation or Fra-1 expression, as well as ATF-2, which is known as a
direct downstream transcription factor of p38 in many other studies
[29] (Fig. 4A). Moreover, treatment of p27−/− cells with SP600125
or PD98059 did not show an inhibition on CREB phosphorylation,
whereas these inhibitors inhibited c-Jun phosphorylation and Fra-1
expression (Fig. 4A). To further test the role of p38 in p27 regulation
of CREB phosphorylation and COX-2 expression, dominant negative
mutant p38 was co-transfected with COX-2-luciferase reporter into
p27−/− MEFs to establish a stable transfectant, p27−/− (DN-p38).
As shown in Fig. 4B and C, speciﬁc inhibition of p38 by ectopic expres-
sion of DN-p38 in p27−/− MEFs impaired CREB phosphorylation and
COX-2 expression upon arsenite treatment compared with those in
p27−/− (vector) transfectant. Consistently, elevation of cox-2 tran-
scription due to arsenite exposure in cox-2 promoter-driven luciferase
reporter assay was also attenuated in DN-p38 transfectant (Fig. 4C).
Previous studies have shown that p38 isoforms have differential biolog-
ical effects [30]. Thus, we compared arsenite-induced COX-2 expression
between cellswith a deﬁciency of p38α (p38α−/−), p38β (p38β−/−)
and p38δ (p38δ−/−) (Fig. 4D). The results showed that knockout of
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2087X. Che et al. / Biochimica et Biophysica Acta 1833 (2013) 2083–2091p38α did not show observable inhibition of COX-2 expression (Fig. 4E),
while deletion of either p38β or p38δ effectively attenuated COX-2
induction by arsenite (Fig. 4F and G), demonstrating that both p38β
and p38δ, but not p38α, were crucial for COX-2 induction by arsenite.
Though p38δ was usually not considered as a target of SB202190, its
involvement in arsenite induced COX-2 expression was still conﬁrmed
here. Consistently, the deﬁciency of p38β or p38δ in p38β−/− or
p38δ−/− cells also impaired CREB phosphorylation (Fig. 4H and I),
demonstrating that both p38β and p38δ are crucial for arsenite-
induced CREB phosphorylation. Taken together, our results indicated
that p27 inhibited arsenite-induced COX-2 expression via attenuating
activation of p38β/p38δ-CREB axis.
3.5. p38-regulated CREB activation was essential for increased COX-2
transcription in p27−/− cells
Our above results strongly indicate that p27 suppresses arsenite-
induced COX-2 transcription and CREB activation, both of which are
regulated by p38. Due to the fact that NFκB has been reported to
play an important role in COX-2 induction by nickel and Cr(VI) in
BEAS 2B cells, we determined whether NFκB was also important in
p27-regulated COX-2 expression following arsenite exposure [31,32].
As shown in Fig. 5A, the distribution of p50 and p65 in nuclear and
cytoplasm did not show observable difference between p27+/+ and
p27−/− cells upon arsenite exposure, indicating that NFκB was not
involved in p27 regulation of COX-2 expression. To evaluate the poten-
tial role of CREB activation in upregulating COX-2 in p27−/− cells, wecompared CREB activation in p27+/+ and p27−/− MEFs, and found
that CREB phosphorylation was also elevated in p27−/− cells in com-
parison to that in p27+/+MEFs (Fig. 5B). To further evaluate whether
CREB is involved in COX-2 expression from arsenite exposure in
p27−/− cells, we applied shRNA to knockdown CREB to test whether
COX-2 induction would be inhibited. As shown in Fig. 5C, CREB expres-
sion and phosphorylation were dramatically knocked down by
transfecting shRNA CREB into p27−/− cells. Knockdown of CREB
expression led to a signiﬁcant inhibition of COX-2 expression at both
the transcriptional level and protein level as a result of arsenite expo-
sure in p27−/− cells (Fig. 5D and E). Our results strongly suggested
that p27 suppressed COX-2 induction speciﬁcally through targeting
the p38β/p38δ-CREB pathway. Together with our previous result, this
ﬁnding has extended understanding underlying of p27 in suppressing
arsenite-induced MAPK and downstream pathways and gene expres-
sion as well as (Fig. 5F).
4. Discussion
p27 was ﬁrst identiﬁed as a CDK inhibitor. It binds to cyclin E-Cdk2
complexes, suspending the cell cycle at the G1 phase [14]. By using
afﬁnity chromatography of cyclin E-Cdk2, this 27-kDa protein was
puriﬁed from cycling-arrest cells for the ﬁrst time and is referred to
as p27 [15]. Early research on p27 knockout mouse revealed that
absence of the p27 gene, which causes excessive cell proliferation and
physical dysfunction such as multiple organ hyperplasias, increased
body size and several kinds of tumor formation [33,34]. These facts
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CDK inhibitor. Later, p27 was proven to work on different CDKs in the
cell nucleus and affect the entire cell cycle [35–37]. As nucleus localiza-
tion of p27 is linked to its CDK-dependent effect, its relocalization can
thereby release inhibitory effects on CDKs and promote cancer develop-
ment [38]. However, other studies of the relationship between p27 and
cancer exhibit evidence showing that relocalized p27 may also affect
cancer development through a CDK-independent pathway. Studies of
the CDK-independent role of p27 indicate that cytoplasma localized
p27 are related to metastatic melanoma and other metastatic diseases
[39]. This effectwas later inferred to be accomplished via the interaction
between p27 and RhoA via binding [40]. Though the above studies have
revealed part of the cyclin/CDK regulatory independent cancer effect of
p27, the CDK-independent effect of tumor suppression in p27 is still
largely unexplored. Our previous work has demonstrated that with
arsenite exposure, p27 can exhibit anticancer effects by suppressing
JNK/c-Jun and HSF-1 pathway activation, thus reducing hsp27 and
hsp70 expression [7]. In this study, we discovered that p27 exhibited
an inhibitory effect on COX-2 induction at the transcriptional level
upon arsenite exposure, speciﬁcally through inhibition of p38β and
p38δ-mediated CREB-dependent pathway, based on the results
obtained from utilizing p27−/− and p38 deﬁcient MEFs as well as
DN-p38 transfectants. These novel ﬁndings provide new mechanistic
information for understanding of p27 tumor suppressor functions
through CDK-independent mechanisms.
Cyclooxygnenase (COX) is the enzyme responsible for biogenesis of
prostanoids, a signaling molecule with multiple functions in various
biological processes, including inﬂammation and cancer development
[41]. Genetic study of COX-2 knockoutmice has revealed a strong corre-
lation between COX-2 expression and cancer development, indicatingthat COX-2 contributes to carcinogenesis and oncogenesis [42,43]. Our
previous ﬁndings also suggest several cancer-related biological effects
of COX-2, including anti-apoptotic effect, cell transformation, and cell
cycle progression in different context [44]. Regarding cell transforma-
tion and cell cycle progression as key steps of carcinogenesis, and apo-
ptotic as a cancer suppression process, we anticipate that COX-2 is a
factor that is positively associated with cancer development. It has
been shown that COX-2 expression is also regulated by various onco-
genes [45]. Thus in our current study, it is reasonable to expect COX-2
induction by arsenite may partly contribute to the carcinogenic effect
of arsenite. This hypothesis is supported by amounts of inﬂammation
studies. It has been reported that cadmium exposure induces HO-1
and COX-2 expression with elevation of overall PGE-2 generation, indi-
cating that COX-2 enzyme activity is increased in presence of HO-1 fol-
lowing cadmium exposure [46]. It has also been reported that arsenite
exposure induces COX-2 expression with signiﬁcantly increasing PGE2
generation and then leads to inﬂammatory effect in rat liver epithelial
cells [47]. Previous studies have demonstrated that p27 knockout
mice have more ﬂorid inﬂammation response, demonstrating the
anti-inﬂammatory function of p27 [48]. Thus, we anticipate that p27-
regulated COX-2 expression exhibits its inﬂammatory response follow-
ing arsenite exposure although HO-1 may exhibit some suppressive
effect on COX-2 enzyme activity and subsequently resulting in some
counterbalance of its inﬂammatory response. This information provides
a signiﬁcant insight into the understanding of anti-inﬂammatory effects
of p27 that extend its anti-oncogene functions. In addition, elucidation
of anti-inﬂammatory effect of p27 via inhibiting COX-2 expression
extends our understanding of chronic inﬂammation-associated carcino-
genic effects of arsenite exposure. Since many metals, such as arsenite,
nickel(II), and chromium(IV), share a similar biological effect on
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p27 has a similar effect on COX-2 induction following exposure of other
metals, such as nickel(II), and chromium(IV) in our future investigation.
While the constitutive isoform of COX-1 remains in most tissues,
the inducible isoform COX-2 is only detectable in certain conditions,
such as tissue and cells with mitogenic stimuli in inﬂammation or in
various types of cancer tissues [49,50]. Activation on a transcriptional
level is an example of one mechanism responsible for COX-2
overexpression in cancer tissues [51]. Transcription factors, such as
NFAT, NFκB, and AP-1, have been veriﬁed to regulate COX-2 transcrip-
tion in various experimental systems [52]. Several selective COX-2
inhibitors have been developed for pharmacologic applications, some
of which are considered to have promising potential for cancer treat-
ment [53,54]. Among these inhibitors, some work at the transcriptional
regulation of COX-2 expression [55]. In the present study, we found
that the transcription factor CREB is required for COX-2 elevation in
p27−/− cells, and that p38β and p38δ, as well as MKK3/6, act as
major kinases responsible for the increased phosphorylation of CREB,
whereas other transcription factors, such as AP-1, does not play a signif-
icant role in mediation of the increased COX-2 expression in p27−/−
cells even though it is also activated following arsenite exposure. This
information may provide the direction for future drug development
targeting COX-2.
p38 is an MAPK family member and was ﬁrst isolated as tyrosine
phosphorylated in response to LPS [56]. Four isoforms of p38 have
been identiﬁed so far: α, β, γ, and δ, each with a unique signaling
pathway [57,58]. Activation of p38 is related to phosphorylation sta-
tus. Among its upstream kinases, MAP kinase kinase 6 can activate
all p38 isoforms via phosphorylation, while MKK3 can only activate
its α, γ, and δ isoforms [21]. Dephosphorylation of p38 involves phos-
phatases that include Protein Phosphatase 1 and Protein Phosphatase
2A [59,60]. p38 can phosphorylate transcription factors such as ATF-2,
and then activate downstream target gene expression [61]. Ourprevious studies also indicated the activation of types of MAPKs and
thus their downstream target upon arsenite exposure [7,62]. Porter
et al. reported that Rac, Rho, MEKK3, and MEKK4 are required for
JNK activation upon arsenite treatment in kidney 293 cells [63].
Moreover, reactive oxygen species (ROS) generation as an important
consequence of arsenite treatment during cellular metabolisms has
been studied in published studies [64,65]. It has been reported that
arsenite-induced generation of ROS mediates MAPK activation
[6,66]. Our unpublished studies also showed that p27 knockout
increases MnSOD expression and hydrogen peroxide generation
(Zheng, X, and Huang, C, unpublished data). Thus, potential contribu-
tion of MnSOD expression and hydrogen peroxide generation in p27
regulation of COX-2 axis is under investigation in our group. In the
current studies, we have identiﬁed that p38β and p38δ, but not
p38α, is regulated by p27 and have conﬁrmed that p38β and p38δ
are crucial for mediating CREB phosphorylation and activation upon
arsenite exposure. Our results reveal the differential effects of p38
isoforms in relation to their various downstream transcription factors,
such as CREB, as well as their speciﬁc cellular biological functions.
The results demonstrated in current studiesﬁgured out the signaling
pathway leading to increased COX-2 induction by arsenite exposure in
p27−/− cells. By evaluating the role of p27 in regulation of COX-2
induction upon arsenite response, we demonstrated the novel function
of p27modulation of p38 activation. p27 exhibits the inhibition of CREB
phosphorylation and activation, and further regulates COX-2 transcrip-
tion. Previous studies have reported much about the correlation
between p27 and MAPK, including p38, but p27 is mostly considered
merely as a CDK inhibitor that is regulated by MAPK [67,68]. However,
our study shows that p27 can reversely regulate p38 phosphorylation,
revealing the crosstalk between p38 and p27 in controlling the complex
anti-cancer mechanism of p27. The CDK-independent function of p27
has been studied frequently but studies are seldom done on inhibition
of tumors via the MAPK pathways. Therefore, to fully elucidate as to
2090 X. Che et al. / Biochimica et Biophysica Acta 1833 (2013) 2083–2091how p27 affects phosphorylation of p38 isoforms will be highly signiﬁ-
cant for the complete understanding of this novel function of p27 in
regulating COX-2 expression, as well as in mediating inﬂammation
and chronic inﬂammation-associated carcinogenic effects.
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CDK cyclin-dependent kinase
COX-2 cyclooxygenase-2
MAPK Mitogen-activated protein kinase
NFκB nuclear factor κB
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